GLP-1 receptor agonist studied for potent appetite regulation, glucose metabolism and body weight reduction. The most researched weight-loss compound in clinical trials worldwide.
CAS: 910463-68-24113.58 Da💉 IM/SQ💊 Oral
Dual GIP/GLP-1 receptor agonist for superior metabolic outcomes. Targets two incretin pathways simultaneously for enhanced insulin sensitivity and significant body weight reduction.
CAS: 1187386-74-04813.45 Da💉 IM/SQ
Triple-agonist targeting GLP-1, GIP and glucagon receptors — the next frontier in metabolic research. Stimulates energy expenditure via glucagon while controlling appetite.
CAS: 2381089-83-2~4482 Da💉 IM/SQ
Long-acting amylin receptor agonist for appetite suppression and weight regulation. Works via distinct pathways from GLP-1.
CAS: 2170621-42-4~3990 Da💉 IM/SQ
5mg + GLP-1 S 5mgYPB.239
$ —
2.5mg + GLP-1 S 2.5mgYPB.240
$ —
Dual GLP-1/glucagon agonist for obesity and MASH research. Glucagon promotes hepatic fat oxidation while GLP-1 reduces appetite.
~4100 Da💉 IM/SQ
OXM-based GLP-1/glucagon dual agonist. Developed for obesity and type 2 diabetes with clinical data showing significant weight reduction.
💉 IM/SQ
Modified HGH fragment (176-191) studied for lipolytic properties without growth-promoting effects. Targets adipose tissue via β3-adrenergic pathways.
CAS: 221231-10-31815.08 Da💉 IM/SQ
Selective NNMT inhibitor for metabolic optimization. Boosts intracellular NAD+, shrinks adipocytes and enhances energy metabolism.
CAS: 42464-96-0159.21 g/mol💉 IM/SQ💊 Oral
Pan-ERR agonist "exercise mimetic." Boosts mitochondrial biogenesis, fatty acid oxidation and aerobic endurance at the cellular level.
CAS: 303760-60-3290.32 g/mol💉 IM/SQ💊 Oral